Aβ1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease, but its definitive diagnosis delays around 12 months. Although the research is highly active in the biomarker field, the absence of specific biomarkers for diagnosis contributes to this long delay. Another strategy of bioma...
Main Authors: | Débora Lanznaster, Rudolf C. Hergesheimer, Salah Eddine Bakkouche, Stephane Beltran, Patrick Vourc’h, Christian R. Andres, Diane Dufour-Rainfray, Philippe Corcia, Hélène Blasco |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/8/2911 |
Similar Items
-
Plasma tau complements CSF tau and P‐tau in the diagnosis of Alzheimer's disease
by: Silvia Fossati, et al.
Published: (2019-12-01) -
Genome-wide network-based pathway analysis of CSF t-tau/Aβ1-42 ratio in the ADNI cohort
by: Wang Cong, et al.
Published: (2017-05-01) -
Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels
by: Taylor J. Maxwell, et al.
Published: (2018-08-01) -
Coumarin derivatives against amyloid-beta 40 – 42 peptide and tau protein
by: Kowalczyk Joanna, et al.
Published: (2022-08-01) -
Effect of long‐term storage in biobanks on cerebrospinal fluid biomarker Aβ1‐42, T‐tau, and P‐tau values
by: Eline A.J. Willemse, et al.
Published: (2017-01-01)